Determination of Sennoside A in Rat Plasma by Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry and Its Application to a Rat Pharmacokinetic Study
{"title":"Determination of Sennoside A in Rat Plasma by Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry and Its Application to a Rat Pharmacokinetic Study","authors":"Jingjing Sun, Yifan Gu, Chunyan Gu, Wen Qi, Feifei Chu, Jiawei Shen","doi":"10.1002/bmc.6049","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>To characterize pharmacokinetic profile of sennoside A in rats after intravenous and oral administration, a simple and sensitive liquid chromatography tandem mass spectrometry method was established and validated for quantitative determination of sennoside A in rat plasma. After prepared by protein precipitation with acetonitrile, sennoside A and internal standard were separated on a Waters ACQUITY HSS T3 (2.1 × 100 mm, 1.8 μm) column using acetonitrile and 5-mM ammonium acetate in water as mobile phase by gradient elution. The method showed excellent linearity over the range of 0.5–1000 ng/mL with acceptable intra- and inter-day precision, accuracy, matrix effect, and recovery. The stability assay indicated that sennoside A was stable in plasma during the sample collection, preparation, and analysis. Next, the method was applied to pharmacokinetic study of sennoside A in rats. After intravenous and intragastric administrated to rats, the concentrations of sennoside A in plasma at different time points were quantitated and the pharmacokinetic parameters were calculated by software of DAS 2.0. Pharmacokinetic parameters suggested that after oral administration, sennoside A was reached to the peak at 2.9–3.6 h with a C<sub>max</sub> value of 13.2–31.7 ng/mL. Sennoside A was eliminated slowly from the plasma with T<sub>1/2</sub> value between 15.4 and 18.3 h. The oral absolute bioavailability was among 0.9%–1.3%, which indicated low blood exposure level.</p>\n </div>","PeriodicalId":8861,"journal":{"name":"Biomedical Chromatography","volume":"39 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Chromatography","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bmc.6049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
To characterize pharmacokinetic profile of sennoside A in rats after intravenous and oral administration, a simple and sensitive liquid chromatography tandem mass spectrometry method was established and validated for quantitative determination of sennoside A in rat plasma. After prepared by protein precipitation with acetonitrile, sennoside A and internal standard were separated on a Waters ACQUITY HSS T3 (2.1 × 100 mm, 1.8 μm) column using acetonitrile and 5-mM ammonium acetate in water as mobile phase by gradient elution. The method showed excellent linearity over the range of 0.5–1000 ng/mL with acceptable intra- and inter-day precision, accuracy, matrix effect, and recovery. The stability assay indicated that sennoside A was stable in plasma during the sample collection, preparation, and analysis. Next, the method was applied to pharmacokinetic study of sennoside A in rats. After intravenous and intragastric administrated to rats, the concentrations of sennoside A in plasma at different time points were quantitated and the pharmacokinetic parameters were calculated by software of DAS 2.0. Pharmacokinetic parameters suggested that after oral administration, sennoside A was reached to the peak at 2.9–3.6 h with a Cmax value of 13.2–31.7 ng/mL. Sennoside A was eliminated slowly from the plasma with T1/2 value between 15.4 and 18.3 h. The oral absolute bioavailability was among 0.9%–1.3%, which indicated low blood exposure level.
为了描述大鼠静脉注射和口服番泻苷 A 的药代动力学特征,建立了一种简单灵敏的液相色谱串联质谱法,用于定量检测大鼠血浆中的番泻苷 A。大鼠血浆中的番泻苷A和内标物经乙腈沉淀蛋白后,用Waters ACQUITY HSS T3 (2.1 × 100 mm, 1.8 μm)色谱柱分离,以乙腈和5-M乙酸铵水溶液为流动相进行梯度洗脱。该方法在 0.5-1000 ng/mL 范围内线性关系良好,日内和日间精密度、准确度、基质效应和回收率均可接受。稳定性测定表明,在样品采集、制备和分析过程中,番泻苷 A 在血浆中的稳定性良好。接着,将该方法应用于大鼠番泻苷 A 的药代动力学研究。给大鼠静脉注射和胃内注射番泻苷 A 后,定量测定不同时间点血浆中番泻苷 A 的浓度,并用 DAS 2.0 软件计算药代动力学参数。药代动力学参数表明,大鼠口服番泻苷 A 后,在 2.9-3.6 h 达到峰值,Cmax 值为 13.2-31.7 ng/mL。番泻苷 A 从血浆中消除的速度较慢,T1/2 值在 15.4 至 18.3 h 之间。
期刊介绍:
Biomedical Chromatography is devoted to the publication of original papers on the applications of chromatography and allied techniques in the biological and medical sciences. Research papers and review articles cover the methods and techniques relevant to the separation, identification and determination of substances in biochemistry, biotechnology, molecular biology, cell biology, clinical chemistry, pharmacology and related disciplines. These include the analysis of body fluids, cells and tissues, purification of biologically important compounds, pharmaco-kinetics and sequencing methods using HPLC, GC, HPLC-MS, TLC, paper chromatography, affinity chromatography, gel filtration, electrophoresis and related techniques.